CVM 241220 3.00C (CVM241220C3000) Stock Options, News & Quotes

0.10
0.000.00%

15min DelayClose Dec 13 16:00 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Dec 12 19:10

🕗Watchlist FRIDAY December 13. NFA. Tired now so I’ll attach the watchlist for Thursday and Wednesday and check those which didn’t run yet. Remember it’s our lucky day tomorrow: Friday 13th

NOTE: Whenever a stock is up, make sure you check its dilution risk - cash on hand because most likely if they are cash-strapped, they will make offering. Scaling out is key. NEVER listen to those who say hold on because if you lose money, they wouldnt care AT ALL.
*************************************
REVERSE...

Jaguar8

Dec 12 08:22

NEWS

$CEL-SCI (CVM.US)$
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
Thursday, 12th December at 9:15 am
• Multikine is the first cancer immunotherapy to show pre-surgical tumor regression in head and neck cancer in just 3 weeks - confirmed by pathology at surgery
• Factors supporting the go-ahead for the 212-person registration study in the target population include:
◦ Multikine led to significant rates of tumor reg...

Stock_Drift

Nov 26 04:28

Premarket Ticks. 5:27am 11/26

$VSee Health (VSEE.US)$ $CEL-SCI (CVM.US)$ $SmartKem (SMTK.US)$ $Volato Group (SOAR.US)$ $Onconetix (ONCO.US)$ $Fusion Fuel Green (HTOO.US)$ $SEALSQ Corp (LAES.US)$ $Semtech (SMTC.US)$ $HA Sustainable Infrastructure (HASI.US)$ $Spectral AI (MDAI.US)$ $T Stamp (IDAI.US)$ $ZenaTech (ZENA.US)$ $Poseida Therapeutics (PSTX.US)$

Trytosaveabit

Nov 7 07:17

News

$CEL-SCI (CVM.US)$ U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
2 MINUTES AGO, 8:15 AM EST
VIA BUSINESSWIRE
• Biomarker used to select patients who are more likely have favorable outcomes, supporting a successful confirmatory Registration Study
• Patients with low PD-L1 expression treated with Multikine in the target population had a 5-year survival of 73% vs. 45% in the control group in the...

Jaguar8

Nov 7 07:15

NEWS

$CEL-SCI (CVM.US)$
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
CEL-SCI (NYSE: CVM) announced FDA agreement on using PD-L1 biomarker for patient selection in its upcoming Multikine Registration Study for head and neck cancer, starting Q1 2025. The study will focus on patients with low PD-L1 tumor expression, following promising results from a previous Phase 3 study where patients showed 73% v...